Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Murphy, Cynthia
Voyage, NCT06741228: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (VOYAGE)	Recruiting	3	200	US	Placebo, MM120 (LSD D-Tartrate)	Mind Medicine, Inc.	Generalized Anxiety Disorder	05/26	11/26
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Terminated	3	1125	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	12/24	12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
deBros, Guy
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Terminated	3	1125	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	12/24	12/24